Pharmacological Treatment Options for Nonalcoholic Steatohepatitis: Resmetirom vs GLP-1 Receptor Agonists

Authors

Debbie Zabel, University of North Dakota

Files

Document Type

Poster

Description

Incidence of nonalcoholic steatohepatitis (NASH) is rising and becoming a leading cause of cirrhosis requiring liver transplantation (Maurice et al., 2018). • Historic management with lifestyle changes and treatment of comorbidities. • March 2024: FDA approved resmetirom, the first medication specifically for the treatment of NASH. • Comparison of GLP-1 receptor agonists and dual GLP/GIP/GCGR receptor agonists with resmetirom for hepatic fat reduction. • Database search of PubMed and Embase yielded 11 studies from an initial 698 articles after filter application for randomized controlled trials and studies published no earlier than 2014. • Resmetirom is superior to GLP-1 agonists for fibrosis improvement in more advanced cases. • Similar efficacy seen between resmetirom and GLP-1 agonists for liver fat reduction in lower stage of fibrosis and nonalcoholic fatty liver disease (NAFLD).

Department

Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

Publication Date

Spring 5-2025

Disciplines

Medicine and Health Sciences

Recommended Citation

Zabel, Debbie, "Pharmacological Treatment Options for Nonalcoholic Steatohepatitis: Resmetirom vs GLP-1 Receptor Agonists" (2025). Physician Assistant Scholarly Project Posters. 338.
https://commons.und.edu/pas-grad-posters/338